one patient received more than 100 cycles of the drug
A damning report found patients with brain tumours were left on chemotherapy for years, despite the treatment being unnecessary and potentially harmful, in a series of serious failures at an NHS trust.
The investigation by the Royal College of Physicians (RCP) examined the care of 20 patients treated by a now-retired clinical oncologist at University Hospitals Coventry and Warwickshire NHS Trust (UHCW).
It found that patients were prescribed the chemotherapy drug temozolomide (TMZ) well beyond the recommended treatment duration, with some receiving it without being properly informed of the risks.
Others were misdiagnosed, given inappropriate treatment or wrongly led to believe they would die if they stopped chemotherapy.
Temozolomide is used to treat brain tumours and has been administered alongside radiotherapy since 2006. However, treatment is not normally recommended beyond 12 monthly cycles.
In the most serious case identified by the review, one patient received more than 100 cycles of the drug over a period of more than 10 years. They subsequently developed an aggressive form of blood cancer associated with previous chemotherapy, particularly drugs such as temozolomide.
The RCP said several aspects of care across all 20 cases were “well below expected standards”, adding that “the patient was given unnecessary treatment that was not based on evidence” in each case.
A recurring concern was the lack of communication and direct medical oversight between the retired oncologist, referred to in the review as Dr Y, and his patients.
Patients typically attended an initial consultation with Dr Y, but their subsequent care was managed by a clinical nurse specialist. The report said ‘there should have been much more direct senior medical oversight’.
The way patients were asked to consent to treatment was another significant concern.
Investigators found little evidence that the potential risks of temozolomide had been properly explained, while some patients who had initially agreed to six cycles continued receiving chemotherapy well beyond that point without giving renewed consent.
Where consent forms were available, the report said they were “often of poor quality, lacking relevant information”.
The review also identified cases in which chemotherapy continued despite “deterioration of the patient’s condition” and “little or no evidence of clinical benefit”.
Some patients were also “incorrectly advised, implicitly or explicitly, that stopping treatment would be harmful”.
The RCP said: “Dr Y appears to have been a difficult individual to engage with, but multiple opportunities for scrutiny and challenge were missed.”
The review was commissioned after UHCW contacted the RCP following concerns about Dr Y’s clinical practice. The oncologist retired in December 2023.
Responding to the findings, trust leaders have apologised to patients and families, acknowledging that failures within its neuro-oncology service resulted in people receiving chemotherapy for years when it was not appropriate.
In a statement, UHCW chief executive Professor Andy Hardy and trust chair Sue Noyes said:
“We are deeply sorry to all the patients and families affected by failures within our neuro-oncology service under the care of retired clinical oncologist Ian Brown.
“We recognise the concern, distress and loss of trust experienced by those who placed their faith in us during some of the most difficult moments of their lives.”
They acknowledged that the report showed how patients’ chemotherapy treatment “was prolonged beyond accepted national guidance, and that opportunities were missed to challenge and oversee these clinical decisions sooner”.
They added: “It also, distressingly, shows that some patients experienced harm because of the care they received.
“This is far below the standards our patients deserve and that we expect. We let you down, and for that we offer our sincere apologies.”
The trust said it had already taken “decisive steps to strengthen our clinical governance and ensure all treatment decisions are made collaboratively”.
It added that an independent review of “speaking up processes” was also underway “to ensure staff feel fully supported and confident in raising any concerns.”
The RCP has recommended that UHCW independently reviews the cases of all living patients who received more than 12 months of temozolomide treatment.
The reviews should establish whether patients have the correct diagnosis and whether their treatment falls within recognised clinical standards.
It has also urged the trust to examine why opportunities to challenge potentially unsafe practices were missed and consider whether further changes are needed to ensure patient safety concerns are addressed more quickly across the organisation.
Meanwhile, legal firm Brabners, which represents more than 40 patients affected by the cases, has called for an independent public inquiry.
The firm said cases had been referred to the police, although no action had been taken so far.








